ExonHit Licenses Merck Rights to RNA Splicing Microarray Patent | GenomeWeb
NEW YORK (GenomeWeb News) - ExonHit Therapeutics has granted Merck a license to its RNA splicing microarray patent, ExonHit said yesterday.
The non-exclusive license gives rights to the patent -- US No. 6,881,571, titled “Qualitative Differential Screening” -- for research use only. The patent has claims directed to microarrays optimized to monitor RNA splicing events, the company said.
ExonHit does not expect to receive more than $150,000 in revenues per year under this agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.